India, Feb. 1 -- This company manufactures APIs towards Cardiovascular health, Antihistamine, Antidiabetic, Antipsychotic, Antimigraine, Parkinson's Disease, Antineoplastic, ADHD Symptoms, Analgesics, Alcohol Abstinence and Bone Resorption Inhibitor is now in focus after reporting its Q3 results with a turnaround in net profit

With a market capitalisation of Rs. 912 cr, the shares of Ind-Swift Laboratories Ltd are currently trading at Rs. 112 per share, increasing 4% in today's market session, making a high of Rs. 118.05, up from its previous close of Rs. 113.34 per share. The stock has gained 8% over the past year, is up 23% year-to-date, and has increased 4% in the last six months.

Q3 Results Quarter-on-Quarter (QoQ) performance Ind-...